V
Vascular Therapies
Vascular Therapies develops a drug-device combination product for perivascular implantation during arteriovenous fistula surgeries
About Vascular Therapies
Vascular Therapies, Inc. is a privately-held, clinical-stage biopharmaceutical company established in 2001. The company is focused on developing solutions to improve outcomes for patients with kidney and vascular diseases by addressing surgical stenosis. Since its inception, the company has secured approximately $124 million in funding over 14 rounds, with its first round in October 2005 and its latest in March 2022, attracting both existing and new investors, including a Fortune 100 global healthcare company.
The company's core focus is the development of Sirogen™, an investigational, proprietary formulation of the drug sirolimus designed for local, perivascular delivery during surgery. This product is delivered via a biodegradable collagen implant placed at the surgical site. The primary application for Sirogen™ is to enhance the outcomes of arteriovenous fistula (AVF) creation, a common procedure for patients with end-stage renal disease who require hemodialysis. AVF failure rates are a significant clinical challenge, and Sirogen™ aims to improve fistula maturation and long-term viability by reducing the stenosis that can occur where the vein and artery are connected.
Vascular Therapies is advancing Sirogen™ through rigorous clinical trials. The initial Phase 3 study, ACCESS, did not meet its primary endpoint; however, a subsequent analysis of a subgroup of patients aged 65 and older showed promising results in AVF maturation and durability. This led to the design of a second Phase 3 trial, ACCESS 2, a multinational, randomized study to validate these findings. Enrollment for the ACCESS 2 study, involving 136 patients across the US and UK, was completed in August 2024, with results anticipated in the second quarter of 2025. The Sirogen™ development program has received Fast Track status and Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for dialysis vascular access indications.
The company is led by CEO John McDermott, who brings nearly three decades of experience from the vascular industry, and founder Dr. Sriram Iyer, who serves as the Chief Scientific Officer. Vascular Therapies operates in the biopharmaceutical and drug delivery market, specifically targeting the unmet needs within the hemodialysis and vascular surgery sectors. Its business model centers on the research, development, and eventual commercialization of Sirogen™ upon receiving regulatory approval, thereby offering a therapeutic solution rather than a medical device to improve surgical outcomes for a high-risk patient population.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 29.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Medical Devices
- Sector
- Biotechnology, Cardiology and cardiovascular, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Mar 2022 | $25M | $100M | Undisclosed | ↗ |
| LATE VCOther financing | Jan 2020 | $17M | $69M | Undisclosed | — |
Growth signals
Latest recorded traffic for Vascular Therapies is 160 monthly website visits, down 91.6% over the last three months. Vascular Therapies's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vascular Therapies in the Cresskill ecosystem
The Vascular Therapies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US Department of Health and Human Services
Series B and later1 investor entered at this stage
- CLCNF Investments LLC
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vascular Therapies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vascular Therapies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









